New data confirms cancer-fighting potential
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Noxopharm Ltd. has announced new data showcasing the cancer-fighting potential of its Sofra technology platform, which enhances immune activation against cancer cells. The CEO expressed optimism about the results and the unique advantages of their immuno-oncology program in addressing unmet needs in cancer treatment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Noxopharm
- Noxopharms Sofra assets to be presented at global conference
- Noxopharm progresses US regulatory strategy
- New data shows SOF-SKN active ingredient efficacy
- Innovative collaboration further expands Sofra platform
- March 2026 Quarterly Activities Report and Appendix 4C
Later from Noxopharm
- SOF-SKN manufacturing begins to ensure clinical trial readi
- Quarterly Activities/Appendix 4C Cash Flow Report
- New preclinical data supports immuno-oncology approach
- Appendix 4E - Preliminary Financial Report
- Novel oligonucleotides data presented at Options Conference
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm